Meetings

6.3a The Committee noted the report and agreed to defer a decision on whether to undertake any future follow up work until after the publication of the annual report on the Diabetes Delivery Plan at the end of 2014.

NDM5328 David Rees (Aberavon)

The National Assembly for Wales:

Notes the report of the Health and Social Care Committee into the implementation of the National Service Framework for diabetes in Wales and its future direction, which was laid in the Table Office on 24 June 2013.

Note: The response of the Minister for Health and Social Services to the report was laid in the Table Office on 9 October 2013.

Supporting documents:

Health and Social Care Committee’s report

Welsh Government’s response

The item started at 16.03

NDM5328 David Rees (Aberavon)

The National Assembly for Wales:

Notes the report of the Health and Social Care Committee into the implementation of the National Service Framework for diabetes in Wales and its future direction, which was laid in the Table Office on 24 June 2013.

The motion was agreed in accordance with Standing Order 12.36.

2.1 The Committee discussed the draft report.

HSC(4)-32-12 paper 1

          Dr Phil Evans, Chair

          Dr Mike Page, Chair, Welsh Endocrine and Diabetes Society

          Julie Lewis, diabetes specialist nurse lead for Wales

          Professor Stephen Bain, Chair, Diabetes Research Network Wales

2.1 The witnesses responded to questions from members of the Committee.

2.2 Dr Evans agreed to provide a copy of the document submitted to the Welsh Government in 2010 on the availability of structured education on type 1 diabetes in Wales.

HSC(4)-32-12 paper 4

David Sissling, Director General, Health, Social Services and Children

Dr Chris Jones, Medical Director NHS Wales and Deputy Chief Medical Officer

2.6 Mr Sissling and Dr Jones responded to questions from members of the Committee.

2.7 Dr Jones agreed to provide additional information in writing on podiatry services across Wales and to provide copies of the letters issued to health boards following the National Diabetes Audit.

HSC(4)-32-12 paper 3

          Lisa Turnbull, Policy & Public Affairs Adviser

          Nicola Davies-Job, Acute Care Adviser

2.4 The witnesses responded to questions from members of the Committee.

2.5 The witnesses agreed to provide additional evidence in writing on the alleged reduction in the number of diabetes specialist nurses in recent years and on the role played by diabetes specialist nurses on the Diabetes Planning and Delivery Groups.

HSC(4)-32-12 paper 2

          Professor Richard Roberts

2.3 Mr Roberts responded to questions from members of the Committee.

HSC(4)-31-12 paper 7

Dr Hugo van Woerden, Director of Health and Healthcare Improvement Division, Public Health Wales

3.3 Dr van Woerden responded to questions from members of the Committee.

HSC(4)-31-12 paper 1 : Abertawe Bro Morgannwg University Health Board

HSC(4)-31-12 paper 2 : Hywel Dda Health Board

HSC(4)-31-12 paper 3 : Aneurin Bevan Health Board

HSC(4)-31-12 paper 4 : Cardiff and Vale University Health Board

HSC(4)-31-12 paper 5 : Betsi Cadwaladr University Health Board

HSC(4)-31-12 paper 6 : Cwm Tâf Health Board

Dr Sharon Hopkins, Director of Public Health, Cardiff and Vale University Health Board

Dr Leo Pinto, Consultant Physician & Clinical Director, Aneurin Bevan Health Board

Dr David Minton, Neighbourhood Care Networks Lead, Aneurin Bevan Health Board

Bronwen John, Head of Partnerships and Network, Aneurin Bevan Health Board

3.1 The witnesses responded to questions from members of the Committee.

3.2 Dr Hopkins agreed to provide information in writing on the specific actions she would recommend to prevent diabetes and its complications.

HSC(4)-30-12 paper 4 – Evidence from the Royal Pharmaceutical Society

          Mair Davies, Chair, Welsh Pharmacy Board

          Paul Gimson, Director for Wales, Royal Pharmaceutical Society

HSC(4)-30-12 paper 5 – Evidence from Alliance Boots

Russell Goodway, Chief Executive, Community Pharmacy Wales

Marc Donovan, Community Pharmacy Wales Board Member and Head of Professional Capability, Alliance Boots

2.4 The witnesses responded to questions from members of the Committee.

2.5 Mr Gimson agreed to share with the Committee a paper on the results of pharmacists providing structured education for diabetes patients.

HSC(4)-30-12 paper 2 – Evidence from the Royal College of Physicians and the Association of British Clinical Diabetologists

Dr Meurig Williams, Royal College of Physicians Regional Adviser for Wales

Dr Aled Roberts, Association of British Clinical Diabetologists

HSC(4)-30-12 paper 3 – Evidence from the British Medical Association

          Dr Ian Millington

Dr Mark Temple

2.2 The witnesses responded to questions from members of the Committee.

2.3 Dr Temple agreed to provide a note for the Committee on the reduction in the number of public health doctors in Wales over recent years.

HSC(4)-30-12 paper 1 – Evidence from Diabetes UK Cymru

          Dai Williams, Director, Diabetes UK Cymru

Jason Harding, Policy Manager, Diabetes UK Cymru

2.1 The witnesses responded to questions from members of the Committee.

HSC(4)-21-12 paper 1

3.1 The Committee agreed the terms of reference for its inquiry into the implementation of the NSF for diabetes in Wales and its future direction, and that it would issue a consultation over the summer recess.

3.2 The Committee agreed its intention to undertake an inquiry into the appraisal of medical technologies and to consult on the scope of the inquiry over the summer recess.